Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway
Open Access
- 24 September 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 12 (1), 1-12
- https://doi.org/10.1038/s41598-022-20164-0
Abstract
Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS). However, the exact molecular mechanisms behind that are not fully understood. There is some evidence showing that MS and MT are interconnected via different pathways: Relapses of MS has a direct correlation with a low level of MT secretion and a growing body of evidence suggest that MT be therapeutic in Experimental Autoimmune Encephalomyelitis (EAE, a recognise animal model of MS) severity. Previous studies have demonstrated that the kynurenine pathway (KP), the main pathway of TRP catabolism, plays a key role in the pathogenesis of MS in humans and in EAE. The present study aimed to investigate whether MT can improve clinical signs in the EAE model by modulating the KP. C57BL/6 mice were induced with EAE and received different doses of MT. Then the onset and severity of EAE clinical symptoms were recorded. Two biological factors, aryl hydrocarbon receptor (AhR) and NAD+ which closely interact in the KP were also assessed. The results indicated that MT treatment at all tested doses significantly decrease the EAE clinical scores and the number of demyelinating plaques. Furthermore, MT treatment reduced the mRNA expression of the KP regulatory enzyme indoleamine 2,3-dioxygenase 1(IDO-1) and other KP enzymes. We also found that MT treatment reduces the mRNA expression of the AhR and inhibits the enzyme Nicotinamide N-Methyltransferase (Nnmt) overexpression leading to an increase in NAD+ levels. Collectively, this study suggests that MT treatment may significantly attenuates the severity of EAE by altering the KP, AhR and NAD+ metabolism.Keywords
This publication has 56 references indexed in Scilit:
- Quinolinic Acid: An Endogenous Neurotoxin with Multiple TargetsOxidative Medicine and Cellular Longevity, 2013
- Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease BrainPLOS ONE, 2013
- Characterization and Comparative Profiling of MicroRNAs in a Sexual Dimorphism Insect, Eupolyphaga sinensis WalkerPLOS ONE, 2013
- Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegenerationThe Journal of Experimental Medicine, 2012
- N -acetylserotonin activates TrkB receptor in a circadian rhythmProceedings of the National Academy of Sciences of the United States of America, 2010
- Antimicrobial and immunoregulatory properties of human tryptophan 2,3‐dioxygenaseEuropean Journal of Immunology, 2009
- The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxinsNature, 2008
- Contrasting Roles for Axonal Degeneration in an Autoimmune versus Viral Model of Multiple Sclerosis: When Can Axonal Injury Be Beneficial?The American Journal of Pathology, 2007
- Protecting Axonal Degeneration by Increasing Nicotinamide Adenine Dinucleotide Levels in Experimental Autoimmune Encephalomyelitis ModelsJournal of Neuroscience, 2006
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001